Furthermore, increased EphA2 expression induced the resistance of osteosarcoma cells to cisplatin in both species, probably through the activation of the Rous sarcoma proto-oncogene (cSRC) and AKT and/or ERK–MAPK pathways, as confirmed by the reduction in their phosphorylation following EphA2 silencing [58]. The gene discussed is SRC; the disease is osteosarcoma.